Phathom Pharmaceuticals, Inc. (PHAT)

Market Cap	498.20M
Revenue (ttm)	n/a
Net Income (ttm)	-178.50M
Shares Out	41.62M
EPS (ttm)	-4.67
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	225,057
Open	11.73
Previous Close	12.00
Day's Range	11.61 - 12.02
52-Week Range	6.10 - 19.95
Beta	0.29
Analysts	Buy
Price Target	22.95 (+91.73%)
Earnings Date	Mar 7, 2023

About PHAT

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 25, 2019
• Employees: 77
• Stock Exchange: NASDAQ
• Ticker Symbol: PHAT

Analyst Forecast

According to 13 analysts, the average rating for PHAT stock is "Buy." The 12-month stock price forecast is $22.95, which is an increase of 91.73% from the latest price.

Price Target

$22.95

(91.73% upside)

Analyst Consensus: Buy